Immunogenicity Risk Assessment for Nucleic Acid Therapeutics: A Comprehensive Evaluation for ASO, siRNA, and Nonvaccine mRNA/LNP Therapies by the IQ Consortium

Joanna Grudzinska‐Goebel(Bayer (Germany)), Vibha Jawa(Bristol-Myers Squibb (Germany)), Amir S. Youssef(Simulation Technologies (United States)), Manuela Braun(Bayer (Germany)), Sophie Tourdot(Pfizer (United States)), Edit Tarcsa(Massachusetts Academy of Math and Science at WPI), Pedro Morais(ProQR Therapeutics (Netherlands)), Sabine Lohmann(Roche (Switzerland)), Linzhi Chen(Boehringer Ingelheim (Germany)), Tao Niu(Sarepta Therapeutics (United States)), Swati Gupta(AbbVie (United States))
Nucleic Acid Therapeutics
November 8, 2025
10.1177/21593337251387423
Cited by 6

Related Papers

The Critical Contribution of Pseudouridine to mRNA COVID-19 Vaccines
|Frontiers in Cell and Developmental Biology|2021|264
Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper
|Molecular Therapy — Methods & Clinical Development|2022|113
2020 White Paper on Recent Issues in Bioanalysis: Vaccine Assay Validation, qPCR Assay Validation, QC for CAR-T Flow Cytometry, NAb Assay Harmonization and ELISpot Validation ( <u>Part 3</u> –Recommendations on Immunogenicity Assay Strategies, NAb Assays, Biosimilars and FDA/EMA Immunogenicity Guidance/Guideline, Gene &amp; Cell Therapy and Vaccine Assays)
|Bioanalysis|2021|60
Generation and characterization of ABT-981, a dual variable domain immunoglobulin (DVD-Ig<sup>TM</sup>) molecule that specifically and potently neutralizes both IL-1α and IL-1β
|mAbs|2015|57
Assay format diversity in pre-clinical immunogenicity risk assessment: Toward a possible harmonization of antigenicity assays
|mAbs|2021|57